Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group

Andrea K. Miyahira; Kenneth J. Pienta; Michael J. Morris; Neil H. Bander; Richard P. Baum; Wolfgang P. Fendler; William Goeckeler; Michael A. Gorin; Hartwig Hennekes; Martin G. Pomper; Oliver Sartor; Scott T. Tagawa; Scott Williams; Howard R. Soule

doi:10.1002/pros.23642

Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group

Andrea K. Miyahira, Kenneth J. Pienta, Michael J. Morris, Neil H. Bander, Richard P. Baum, Wolfgang P. Fendler, William Goeckeler, Michael A. Gorin, Hartwig Hennekes, Martin G. Pomper, Oliver Sartor, Scott T. Tagawa, Scott Williams, Howard R. Soule

School of Medicine

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

Introduction: The Prostate Cancer Foundation (PCF) convened a PSMA-Directed Radionuclide Scientific Working Group on November 14, 2017, at Weill Cornell Medicine, New York, NY. Methods: The meeting was attended by 35 global investigators with expertise in prostate cancer biology, radionuclide therapy, molecular imaging, prostate-specific membrane antigen (PSMA)-targeted agents, drug development, and prostate cancer clinical trials. The goal of this meeting was to discuss the potential for using PSMA-targeted radionuclide agents for the treatment of advanced prostate cancer and to define the studies and clinical trials necessary for validating and optimizing the use of these agents. Results: Several major topic areas were discussed including the overview of PSMA biology, lessons and applications of PSMA-targeted PET imaging, the nuances of designing PSMA-targeted radionuclide agents, clinical experiences with PSMA-targeted radionuclides, PCF-funded projects to accelerate PSMA-targeted radionuclide therapy, and barriers to the use of radionuclide treatments in widespread clinical practice. Discussion: This article reviews the major topics discussed at the meeting with the goal of promoting research that will validate and optimize the use of PSMA-targeted radionuclide therapies for the treatment of advanced prostate cancer.

Original language	English (US)
Pages (from-to)	775-789
Number of pages	15
Journal	Prostate
Volume	78
Issue number	11
DOIs	https://doi.org/10.1002/pros.23642
State	Published - Aug 1 2018

Keywords

clinical trials
medical oncology
nuclear medicine
prostate-specific membrane antigen (PSMA)
radiation therapy
radiology
radionuclides
radiopharmaceuticals
urology

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1002/pros.23642

Cite this

Miyahira, A. K., Pienta, K. J., Morris, M. J., Bander, N. H., Baum, R. P., Fendler, W. P., Goeckeler, W., Gorin, M. A., Hennekes, H., Pomper, M. G., Sartor, O., Tagawa, S. T., Williams, S., & Soule, H. R. (2018). Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. Prostate, 78(11), 775-789. https://doi.org/10.1002/pros.23642

@article{c05361fbe1484624bd89c8df54191d37,

title = "Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group",

abstract = "Introduction: The Prostate Cancer Foundation (PCF) convened a PSMA-Directed Radionuclide Scientific Working Group on November 14, 2017, at Weill Cornell Medicine, New York, NY. Methods: The meeting was attended by 35 global investigators with expertise in prostate cancer biology, radionuclide therapy, molecular imaging, prostate-specific membrane antigen (PSMA)-targeted agents, drug development, and prostate cancer clinical trials. The goal of this meeting was to discuss the potential for using PSMA-targeted radionuclide agents for the treatment of advanced prostate cancer and to define the studies and clinical trials necessary for validating and optimizing the use of these agents. Results: Several major topic areas were discussed including the overview of PSMA biology, lessons and applications of PSMA-targeted PET imaging, the nuances of designing PSMA-targeted radionuclide agents, clinical experiences with PSMA-targeted radionuclides, PCF-funded projects to accelerate PSMA-targeted radionuclide therapy, and barriers to the use of radionuclide treatments in widespread clinical practice. Discussion: This article reviews the major topics discussed at the meeting with the goal of promoting research that will validate and optimize the use of PSMA-targeted radionuclide therapies for the treatment of advanced prostate cancer.",

keywords = "clinical trials, medical oncology, nuclear medicine, prostate-specific membrane antigen (PSMA), radiation therapy, radiology, radionuclides, radiopharmaceuticals, urology",

author = "Miyahira, {Andrea K.} and Pienta, {Kenneth J.} and Morris, {Michael J.} and Bander, {Neil H.} and Baum, {Richard P.} and Fendler, {Wolfgang P.} and William Goeckeler and Gorin, {Michael A.} and Hartwig Hennekes and Pomper, {Martin G.} and Oliver Sartor and Tagawa, {Scott T.} and Scott Williams and Soule, {Howard R.}",

note = "Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",

year = "2018",

month = aug,

day = "1",

doi = "10.1002/pros.23642",

language = "English (US)",

volume = "78",

pages = "775--789",

journal = "Prostate",

issn = "0270-4137",

publisher = "Wiley-Liss Inc.",

number = "11",

}

TY - JOUR

T1 - Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group

AU - Miyahira, Andrea K.

AU - Pienta, Kenneth J.

AU - Morris, Michael J.

AU - Bander, Neil H.

AU - Baum, Richard P.

AU - Fendler, Wolfgang P.

AU - Goeckeler, William

AU - Gorin, Michael A.

AU - Hennekes, Hartwig

AU - Pomper, Martin G.

AU - Sartor, Oliver

AU - Tagawa, Scott T.

AU - Williams, Scott

AU - Soule, Howard R.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Introduction: The Prostate Cancer Foundation (PCF) convened a PSMA-Directed Radionuclide Scientific Working Group on November 14, 2017, at Weill Cornell Medicine, New York, NY. Methods: The meeting was attended by 35 global investigators with expertise in prostate cancer biology, radionuclide therapy, molecular imaging, prostate-specific membrane antigen (PSMA)-targeted agents, drug development, and prostate cancer clinical trials. The goal of this meeting was to discuss the potential for using PSMA-targeted radionuclide agents for the treatment of advanced prostate cancer and to define the studies and clinical trials necessary for validating and optimizing the use of these agents. Results: Several major topic areas were discussed including the overview of PSMA biology, lessons and applications of PSMA-targeted PET imaging, the nuances of designing PSMA-targeted radionuclide agents, clinical experiences with PSMA-targeted radionuclides, PCF-funded projects to accelerate PSMA-targeted radionuclide therapy, and barriers to the use of radionuclide treatments in widespread clinical practice. Discussion: This article reviews the major topics discussed at the meeting with the goal of promoting research that will validate and optimize the use of PSMA-targeted radionuclide therapies for the treatment of advanced prostate cancer.

AB - Introduction: The Prostate Cancer Foundation (PCF) convened a PSMA-Directed Radionuclide Scientific Working Group on November 14, 2017, at Weill Cornell Medicine, New York, NY. Methods: The meeting was attended by 35 global investigators with expertise in prostate cancer biology, radionuclide therapy, molecular imaging, prostate-specific membrane antigen (PSMA)-targeted agents, drug development, and prostate cancer clinical trials. The goal of this meeting was to discuss the potential for using PSMA-targeted radionuclide agents for the treatment of advanced prostate cancer and to define the studies and clinical trials necessary for validating and optimizing the use of these agents. Results: Several major topic areas were discussed including the overview of PSMA biology, lessons and applications of PSMA-targeted PET imaging, the nuances of designing PSMA-targeted radionuclide agents, clinical experiences with PSMA-targeted radionuclides, PCF-funded projects to accelerate PSMA-targeted radionuclide therapy, and barriers to the use of radionuclide treatments in widespread clinical practice. Discussion: This article reviews the major topics discussed at the meeting with the goal of promoting research that will validate and optimize the use of PSMA-targeted radionuclide therapies for the treatment of advanced prostate cancer.

KW - clinical trials

KW - medical oncology

KW - nuclear medicine

KW - prostate-specific membrane antigen (PSMA)

KW - radiation therapy

KW - radiology

KW - radionuclides

KW - radiopharmaceuticals

KW - urology

UR - http://www.scopus.com/inward/record.url?scp=85046788700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046788700&partnerID=8YFLogxK

U2 - 10.1002/pros.23642

DO - 10.1002/pros.23642

M3 - Review article

C2 - 29717499

AN - SCOPUS:85046788700

SN - 0270-4137

VL - 78

SP - 775

EP - 789

JO - Prostate

JF - Prostate

IS - 11

ER -

Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this